These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21093499)

  • 1. Genome-wide RNAi screens in African trypanosomes identify the nifurtimox activator NTR and the eflornithine transporter AAT6.
    Baker N; Alsford S; Horn D
    Mol Biochem Parasitol; 2011 Mar; 176(1):55-7. PubMed ID: 21093499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nitroheterocyclic drug resistance mechanisms in Trypanosoma brucei.
    Wyllie S; Foth BJ; Kelner A; Sokolova AY; Berriman M; Fairlamb AH
    J Antimicrob Chemother; 2016 Mar; 71(3):625-34. PubMed ID: 26581221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genome-wide RNAi screens in bloodstream form trypanosomes identify drug transporters.
    Schumann Burkard G; Jutzi P; Roditi I
    Mol Biochem Parasitol; 2011 Jan; 175(1):91-4. PubMed ID: 20851719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes.
    Wilkinson SR; Taylor MC; Horn D; Kelly JM; Cheeseman I
    Proc Natl Acad Sci U S A; 2008 Apr; 105(13):5022-7. PubMed ID: 18367671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A molecular mechanism for eflornithine resistance in African trypanosomes.
    Vincent IM; Creek D; Watson DG; Kamleh MA; Woods DJ; Wong PE; Burchmore RJ; Barrett MP
    PLoS Pathog; 2010 Nov; 6(11):e1001204. PubMed ID: 21124824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug resistance in human African trypanosomiasis.
    Barrett MP; Vincent IM; Burchmore RJ; Kazibwe AJ; Matovu E
    Future Microbiol; 2011 Sep; 6(9):1037-47. PubMed ID: 21958143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trypanosoma brucei eflornithine transporter AAT6 is a low-affinity low-selective transporter for neutral amino acids.
    Mathieu C; González Salgado A; Wirdnam C; Meier S; Grotemeyer MS; Inbar E; Mäser P; Zilberstein D; Sigel E; Bütikofer P; Rentsch D
    Biochem J; 2014 Oct; 463(1):9-18. PubMed ID: 24988048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-throughput decoding of antitrypanosomal drug efficacy and resistance.
    Alsford S; Eckert S; Baker N; Glover L; Sanchez-Flores A; Leung KF; Turner DJ; Field MC; Berriman M; Horn D
    Nature; 2012 Jan; 482(7384):232-6. PubMed ID: 22278056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis.
    Sokolova AY; Wyllie S; Patterson S; Oza SL; Read KD; Fairlamb AH
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2893-900. PubMed ID: 20439607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the substrate preference of a type I nitroreductase to develop antitrypanosomal quinone-based prodrugs.
    Hall BS; Meredith EL; Wilkinson SR
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5821-30. PubMed ID: 22948871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forward Genetics in African Trypanosomes.
    Hutchinson S; Glover L
    Methods Mol Biol; 2020; 2116():339-352. PubMed ID: 32221930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating 5-nitrofurans as trypanocidal agents.
    Bot C; Hall BS; Alvarez G; Di Maio R; González M; Cerecetto H; Wilkinson SR
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1638-47. PubMed ID: 23335745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deletion of the Trypanosoma brucei superoxide dismutase gene sodb1 increases sensitivity to nifurtimox and benznidazole.
    Prathalingham SR; Wilkinson SR; Horn D; Kelly JM
    Antimicrob Agents Chemother; 2007 Feb; 51(2):755-8. PubMed ID: 17145786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic dissection of drug resistance in trypanosomes.
    Alsford S; Kelly JM; Baker N; Horn D
    Parasitology; 2013 Oct; 140(12):1478-91. PubMed ID: 23552488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trypanocidal activity of nitroaromatic prodrugs: current treatments and future perspectives.
    Wilkinson SR; Bot C; Kelly JM; Hall BS
    Curr Top Med Chem; 2011; 11(16):2072-84. PubMed ID: 21619510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Untargeted metabolomics reveals a lack of synergy between nifurtimox and eflornithine against Trypanosoma brucei.
    Vincent IM; Creek DJ; Burgess K; Woods DJ; Burchmore RJ; Barrett MP
    PLoS Negl Trop Dis; 2012; 6(5):e1618. PubMed ID: 22563508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites.
    Hall BS; Bot C; Wilkinson SR
    J Biol Chem; 2011 Apr; 286(15):13088-95. PubMed ID: 21345801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic Review and Meta-Analysis on Human African Trypanocide Resistance.
    Kasozi KI; MacLeod ET; Welburn SC
    Pathogens; 2022 Sep; 11(10):. PubMed ID: 36297157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.
    Priotto G; Kasparian S; Mutombo W; Ngouama D; Ghorashian S; Arnold U; Ghabri S; Baudin E; Buard V; Kazadi-Kyanza S; Ilunga M; Mutangala W; Pohlig G; Schmid C; Karunakara U; Torreele E; Kande V
    Lancet; 2009 Jul; 374(9683):56-64. PubMed ID: 19559476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model.
    Dauchy FA; Bonhivers M; Landrein N; Dacheux D; Courtois P; Lauruol F; Daulouède S; Vincendeau P; Robinson DR
    PLoS Negl Trop Dis; 2016 Nov; 10(11):e0005125. PubMed ID: 27855164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.